Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Asset Writedowns and Impairment (2022)

Historic Asset Writedowns and Impairment for UroGen Pharma (URGN) over the last 1 years, with Q4 2022 value amounting to $255000.0.

  • UroGen Pharma's Asset Writedowns and Impairment changed N/A to $255000.0 in Q4 2022 from the same period last year, while for Dec 2023 it was $605000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $870000.0 for FY2022, which is N/A changed from last year.
  • Per UroGen Pharma's latest filing, its Asset Writedowns and Impairment stood at $255000.0 for Q4 2022.
  • In the past 5 years, UroGen Pharma's Asset Writedowns and Impairment registered a high of $350000.0 during Q3 2022, and its lowest value of $255000.0 during Q4 2022.